Inhalation Drug Delivery News

1. Honeywell And Recipharm To Speed Development Of Inhalers With A Near-Zero Global Warming Potential Propellant 8/17/2023

   Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.

2. NIH And Exothera Collaborate To Produce GMP Intranasal Vaccine Against SARS-CoV-2 For Clinical Phase I/II Trial In Africa And US 8/16/2023

   The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, oncolytic viruses, and nucleic acid-based therapeutics, to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2. As part of the Cooperative Research and Development Agreement, CRADA, they will be joined by researchers from Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Dartmouth’s Geisel School of Medicine with special expertise in mucosal immunity and the design and conduct of early phase clinical trials.

3. Advent Therapeutics Awarded $3M NIH Grant For Novel Neonatal Lung Therapy 7/18/2023

   Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.

4. Strategic Partnership For Dose Counter Technology Production 7/11/2023

   Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart, a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. 

5. Meissa Vaccines Enters Into cGMP Manufacturing Agreement For Pediatric RSV Vaccine Candidate For Phase 2 Clinical Trials 6/28/2023

   Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced it has entered into a manufacturing agreement with Exothera S.A. (“Exothera”), a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO) delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.

6. Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation For Clopidogrel That Received IND Approval 6/27/2023

   Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

7. Hovione And H&T Presspart Extend Partnership To Advance High Efficiency Device Technology For Dry Powder Inhalation Formulation Delivery 5/3/2023

   Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform.

8. Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving The Important Milestone In Formulation Capability 4/19/2023

   Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was recently granted the "Drug Manufacturing License" (C Certificate) by the Jiangsu Medical Products Administration, a branch of the Chinese National Medical Products Administration (NMPA).

9. Harm Reduction Therapeutics And Catalent Sign Commercial Supply Agreement For Naloxone Nasal Spray To Reverse Opioid Overdoses 3/23/2023

   Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement.

10. Stevanato Group Collaborates With Recipharm To Develop And Manufacture Pre-Fillable Syringes For Use In A New Soft Mist Inhaler For The Inhalation Of Sensitive Biological Products 3/16/2023

    The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Recipharm’s proprietary soft mist inhalers.